• Simona Ruxandra VOLOVAT “Grigore T. Popa” University of Medicine and Pharmacy Iasi
  • Cristian Constantin VOLOVAT “Grigore T. Popa” University of Medicine and Pharmacy Iasi


Hepatocellular carcinoma (HCC) is the commonest primary cancer of the liver, with a poor prognosis in advanced setting. Current treatment for advanced HCC includes mainly sorafenib and more recently approved regorafenib and nivolumab, as chemotherapy has shown little benefit. However, the modest benefit and the low response rate from systemic treatments suggest an increased need for new strategies. Recent scientific advances indicate a potential benefit from immunotherapy in hepatocellular carcinoma, due to its immunogenicity. Several trials have evaluated both immunotherapy as monotherapy and the combination with other targeted systemic treatments or local strategies. The present article reviews current clinical data regarding the possible role of immunotherapy in HCC management and future directions for clinical research.

Author Biographies

Simona Ruxandra VOLOVAT, “Grigore T. Popa” University of Medicine and Pharmacy Iasi

Faculty of Medicine

Cristian Constantin VOLOVAT, “Grigore T. Popa” University of Medicine and Pharmacy Iasi

Faculty of Medicine


1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics 2012. CA Cancer J Clin 2015; 65(2): 87-108.
2. Volk ML, Marrero JA. Early detection of liver cancer: diagnosis and management. Curr Gastroenterol Rep 2008; 10(1): 60-66.
3. Trad D, Bibani N, Sabbah M, Elloumi H, Gargouri D, Ouakaa A et al. Known, new and emerging risk factors of hepatocellular carcinoma (review). Presse Med 2017; 46(11): 1000-1007.
4. Llovet JM, Bustamante J, Castells A, Vilana R, Ayuso MDC, Sala M, et al. Natural history of un-treated nonsurgical hepatocellular carcinoma: Rationale for the design and evaluation of therapeutic trials. Hepatology 1999; 29(1): 62-66.
5. Miron I, Diaconescu S, Aprodu G, Ioniuc I, Diaconescu MR, Miron L. Diagnostic Difficulties in a Pediatric Insulinoma: A Case Report. Medicine 2016; 95(11): e3045.
6. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc J-F et al. Sorafenib in Advanced Hepa-tocellular Carcinoma. N Engl J Med 2008; 359(4): 378-390.
7. Bruix J, Qin S, Merle P, Granito A, Huang Y-H, Bodoky G, et al. Regorafenib for patients with hepa-tocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomized, double-blind, placebo-controlled, phase 3 trial. Lancet 2017; 389(7): 56-66.
8. El-Khoueiry AB, Sangro B, Yau T, Crocenzi TS, Kudo M, Hsu C et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet 2017; 24(389): 2492-502.
9. Ally A, Balasundaram M, Carlsen R, Chuah E, Clarke A, Dhalla N et al. Comprehensive and Integra-tive Genomic Characterization of Hepatocellular Carcinoma. Cell 2017; 169(7): 1327-1341.
10. Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA, Kinzler KW. Cancer genome landscapes. Science 2013; 339(6127): 1546-1558.
11. Yoong KF, McNab G, Hübscher SG, Adams DH. Vascular adhesion protein-1 and ICAM-1 support the adhesion of tumor-infiltrating lymphocytes to tumor endothelium in human hepatocellular carci-noma. J Immunol 1998; 160(8): 3978-3988.
12. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012; 12(4): 252-264.
13. Han Y, Chen Z, Yang Y, Jiang Z, Gu Y, Liu Y et al. Human CD14 + CTLA-4 + regulatory dendritic cells suppress T-cell response by cytotoxic T-lymphocyte antigen-4-dependent IL-10 and indoleamine-2,3-dioxygenase production in hepatocellular carcinoma. Hepatology 2014; 59(2): 567-579.
14. Unitt E, Marshall A, Gelson W, Rushbrook SM, Davies S, Vowler SL et al. Tumour lymphocytic infiltrate and recurrence of hepatocellular carcinoma following liver transplantation. J Hepatol 2006; 45(2): 246-253.
15. Sangro B, Gomez-Martin C, de la Mata M, Iñarrairaegui M, Garralda E, Barrera P, et al. A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C. J Hepatol 2013; 59(1): 81-88.
16. Duffy AG, Ulahannan S V., Makorova-Rusher O, Rahma O, Wedemeyer H, Pratt D, et al. Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma. J Hepatol 2017; 66(3): 545-551.
17. Nakamoto N, Kaplan DE, Coleclough J, Li Y, Valiga ME, Kaminski M, et al. Functional Restoration of HCV-Specific CD8 T Cells by PD-1 Blockade Is Defined by PD-1 Expression and Compartmen-talization. Gastroenterology 2008; 134(7): 1927-1937.
18. Nakamoto N, Cho H, Shaked A, Olthoff K, Valiga ME, Kaminski M, et al. Synergistic Reversal of Intrahepatic HCV-Specific CD8 T Cell Exhaustion by Combined PD-1/CTLA-4 Blockade. Gale M, editor. PLoS Pathog 2009; 5(2): e1000313.
19. Oh SY, Jun HJ, Park SJ, Park IK, Lim GJ, Yu Y, et al. A randomized phase II study to assess the effectiveness of fluid therapy or intensive nutritional support on survival in patients with advanced cancer who cannot be nourished via enteral route. J Palliat Med 2014; 17: 1266-1270.
20. Donkor MK, Sarkar A, Li MO. Tgf-β1 produced by activated CD4(+) T Cells Antagonizes T Cell Surveillance of Tumor Development. Oncoimmunology. Taylor & Francis 2012; 1(2): 162-171.
21. Zerbini A, Pilli M, Penna A, Pelosi G, Schianchi C, Molinari A, et al. Radiofrequency Thermal Abla-tion of Hepatocellular Carcinoma Liver Nodules Can Activate and Enhance Tumor-Specific T-Cell Responses. Cancer Res 2006; 66(2): 1139-1146.
22. Twyman-Saint Victor C, Rech AJ, Maity A, Rengan R, Pauken KE, Stelekati E, et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature 2015; 520(7547): 373-377.
23. Calderaro J, Rousseau B, Amaddeo G, Mercey M, Charpy C, Costentin C, et al. Programmed death ligand 1 expression in hepatocellular carcinoma: Relationship With clinical and pathological features. Hepatology 2016; 64(6): 2038-2046.